Dr. Jonathan S. Maltz, PhD, Lexington's lead researcher, chief scientific adviser and one of the driving forces behind the development of the HeartSentry technology, notes: "I am really excited to report that the Gen-1 HeartSentry devices are working well. All the machines are functioning within their operational parameters and delivering excellent results, and the data is being collected as designed. After 15 years of effort, it's truly remarkable to watch our hard work undergoing rigorous examination in a clinical environment. I am watching events closely and at this point couldn't be happier."
HeartSentry was designed as a diagnostic device offering a new approach to non-invasive measurement and monitoring of cardiovascular health by assessing the function of a patient's vascular endothelium, the vital innermost lining of the cardiovascular system. The company designed HeartSentry to be accurate, quick and cost-effective, with the intent to position it to become the standard of care for cardiologists, general practitioners and ultimately patients for first-line evaluation of cardiovascular health.
Lexington's president, Eric Willis, advises: "It has been gratifying to watch our first patients providing the researchers with the beginning of what we believe will become a wave of consistently replicable data in the days and weeks ahead. We have been advised that the investigative team intends to increase the first cohort of patients to an enrolment that will generate ample data requiring a break in mid-March to collate and assess the initial results. Based on their assessment, activities for a second round of enrolment and additional studies could commence as early as the end of the month. We anticipate this process to be repeated several times as we move ahead to build the requisite data sets for our formal submission to the FDA. Needless to say, the early results have produced lots of smiling faces, and we are beginning to accelerate a number of strategic initiatives to ensure we are fully prepared to move quickly upon completion of the study. It's an exciting time at Lexington, and we are all very proud of what we have been able to accomplish in such a short time. I want to personally thank all our investors, as we wouldn't be here today without your commitment and help."
About Lexington Biosciences Inc.
When you analyze the words of Jonathan Malta and Eric Willis it seems clear that many gave taken a position and now are going to be patient being confident of s positive outcome. The ones riding the trend up have seen the share price level out and so have left . But I'm very excited to see where this company can go. With FDA approval and every family doctor wanting a device to give a more thorough check up....where will stock price go to? Could it go to 5 dollars a share in say 1 year?
